Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure
Protocol #: D6972C00002
Indication: CKD & HTN
GFR: 30-75
Principal Investigator: Ankit Mehta, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246